Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

ABSTRACT:

Aims

Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes.

Materials and methods

Obese adults without diabetes (N = 50; aged 18-70 years; body mass index, 30-45 kg/m² ) were initially randomized to double-blind oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or to placebo. They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

Results

Of the original 25 dapagliflozin + exenatide-treated and 25 placebo-treated participants, respec

SUBMITTER: Lundkvist P 

PROVIDER: S-EPMC5575470 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature